Hostname: page-component-7b9c58cd5d-7g5wt Total loading time: 0 Render date: 2025-03-15T22:48:23.963Z Has data issue: false hasContentIssue false

Analysis of the Effect of Desvenlafaxine on Anxiety Symptoms Associated with Major Depressive Disorder: Pooled Data from 9 Short-Term, Double-blind, Placebo-Controlled Trials

Published online by Cambridge University Press:  07 November 2014

Karen A. Tourian*
Affiliation:
CR&D Neuroscience, Wyeth, a company of the Pfizer Group
Qin Jiang
Affiliation:
Pfizer Inc, formerly Wyeth Research
Philip T. Ninan
Affiliation:
Pfizer Inc, formerly Wyeth Research
*
Karen A. Tourian, MD, Wyeth, a company of the Pfizer Group, Division Wyeth Research, Coeur Défense, Tour A, La Défense 4, 110 Esplanade du Générate de Gaulle 92931 Paris, La Défense Cedex, France. Tel: 33-01-41-02-78-10; Fax:, 33-01-41-02-74-79. E-mail:, TOURIAK@wyeth.com.
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Background: This analysis evaluated the effects of the serotonin-norepinephrine reuptake inhibitor, desvenlafaxine (administered as desvenlafaxine succinate), on anxiety symptoms associated with depression.

Methods: Data were pooled from 9 randomized, placebo-controlled, double-blind, 8 week studies of desvenlafaxine (50-400 mg/day, fixed or flexible dose) in patients with major depressive disorder (MDD), without a primary anxiety diagnosis. Changes from baseline in scores on the anxiety/somatization factor of the 17-item Hamilton Rating Scale for Depression (HAM-D17) and on the Covi Anxiety Scale at the final evaluation (last observation carried forward) were compared between desvenlafaxine and placebo groups using analysis of covariance.

Results: In the overall data set (intent to treat n=2,913 [desvenlafaxine, n=1,805; placebo, n=1,108]), desvenlafaxine was associated with significantly greater reductions compared with placebo in scores on the HAM-D17 anxiety/somatization factor (-3.41 vs -2.92, P<.001) and Covi Anxiety Scale (-1.35 vs -1.04, P<.001). In the subset of fixed-dose studies, significant differences were observed for all dose groups on the HAM-D17 anxiety/somatization factor (P≤.OH), and for the 50, 100, and 200 mg/day dose groups on the Covi Anxiety Scale (all P≤.015 vs placebo).

Conclusions: Desvenlafaxine was associated with significantly greater improvement in anxiety symptoms compared with placebo in patients with MDD.

Type
Original Research
Copyright
Copyright © Cambridge University Press 2010

References

REFERENCES

1.Fawcett, J, Clark, DC, Scheftner, WA, Gibbons, RD. Assessing anhedonia in psychiatric patients. Arch Gen Psychiatry. 1983;40:7384.Google Scholar
2.Fava, M, Alpert, JE, Carmin, CN, et al.Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*TD. Psychol Med. 2004;34:12991308.Google Scholar
3.Fava, M, Rush, AJ, Alpert, JE, et al.Difference in treatment outcome In outpatients with anxious versus nonanxlous depression: A STAR*D report. Am J Psychiatry. 2008;165:342351.Google Scholar
4.Davidson, JR, Meoni, P, Haudiquet, V, Cantillon, M, Hackett, D. Achieving remission with ven-lafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. Depress Anxiety. 2002;16:413.Google Scholar
5.Joffe, RT, Bagby, RM, Levitt, A. Anxious and nonanxious depression. Am J Psychiatry. 1993;150:12571258.Google Scholar
6.Tollefson, GD, Holman, SL, Sayler, ME, Potvin, JH. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. J Clin Psychiatry. 1994;55:5059.Google Scholar
7.Nelson, JC. Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials. Depress Anxiety. 2010;27:1218.Google Scholar
8.Keller, MB, Krystal, JH, Hen, R, Neumelster, A, Simon, NM. Untangling depression and anxiety: clinical challenges. J Clin Psychiatry. 2005;66:14771484.Google Scholar
9.Soomro, GM, Altman, D, Rajagopal, S, Oakley-Browne, M. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev. 2008;(1):CD001765.Google Scholar
10.Dell'Osso, B, Nestadt, G, Allen, A, Hollander, E. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review. J Clin Psychiatry. 2006;67:600610.Google Scholar
11.Pollack, M, Mangano, R, Entsuah, R, Tzanls, E, Simon, NM, Zhang, Y. A randomized controlled trial of venlafaxlne ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology(Berl). 2007;194:233242.Google Scholar
12.Katon, WJ. Clinical practice. Panic disorder. N Engl J Med. 2006;354:23602367.Google Scholar
13.Davidson, JR. Pharmacotherapy of social anxiety disorder: what does the evidence tell us? J Clin Psychiatry. 2006;67(suppl 12):2026.Google Scholar
14.Frlcchione, G. Clinical practice. Generalized anxiety disorder. N Engl J Med. 2004;351:675682.Google Scholar
15.Ballenger, JC. Overview of different pharmacotherapies for attaining remission in generalized anxiety disorder. J Clin Psychiatry. 2001;62(suppl 19):1119.Google Scholar
16.Feighner, JP. Entsuah, AR, McPherson, MK. Efficacy of once-daily venlafaxlne extended release (XR) for symptoms of anxiety in depressed outpatients. J Affect Disord. 1998;47:5562.Google Scholar
17.Nutt, DJ. Care of depressed patients with anxiety symptoms. J Clin Psychiatry. 1999;60(suppl 17):2327.Google Scholar
18.Papakostas, GI, Trivedl, MH, Alpert, JE, et al.Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms In major depressive disorder: a meta-analysis of Individual patient data from 10 double-blind, randomized clinical trials. J Psychiatr Res. 2008;42:134140.Google Scholar
19.Deecher, DC, Beyer, CE, Johnston, Get al.Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006;318:657665.Google Scholar
20.Desvenlafaxine [package insert]. Collegeville, PA: Wyeth Pharmaceuticals; 2008.Google Scholar
21.Septien-Velez, L, Pitrosky, B, Padmanabhan, SK, Germain, J-M, Tourian, KA. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate In the treatment of major depressive disorder. Int Clin Psychopharmacol. 2007;22:338347.Google Scholar
22.DeMartinis, NA, Yeung, PP, Entsuah, R, Manley, AL. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry. 2007;68:677688.Google Scholar
23.Liebowitz, M, Yeung, PP, Entsuah, R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry. 2007;68:16631672.Google Scholar
24.Liebowitz, M, Manley, AL, Padmanabhan, SK, Ganguly, R, Tummala, R, Tourian, KA. Efficacy, safety, and tolerabillty of desvenlafaxine 50 mg/d and 100 mg/d in outpatients with major depressive disorder. Curr Med Res Opin. 2008;24:18771890.Google Scholar
25.Boyer, P, Montgomery, S, Lepola, U, et al.Efficacy, safety, and tolerabillty of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder In a placebo-controlled trial. Int Clin Psychopharmacol. 2008;23:243253.Google Scholar
26.Rudolph, RL, Entsuah, R, Chitra, R. A meta-analysis of the effects of venlafaxlne on anxiety associated with depression. J Clin Psychopharmacol. 1998;18:136144.Google Scholar
27.Dunner, DL, Goldstein, DJ, Mallinckrodt, C, Lu, Y, Detke, MJ. Duloxetine in treatment of anxiety symptoms associated with depression. Depress Anxiety. 2003;18:5361.Google Scholar
28.Rynn, M, Russell, J, Erickson, J, et al.Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety. 2008;25:182189.Google Scholar
29.Lleberman, DZ, Montgomery, SA, Tourian, KAet al.A pooled analysis of two placebo-controlled trials of desvenlafaxine In major depressive disorder. Int Clin Psychopharmacol. 2008;23:188197.Google Scholar
30.Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th ed. Washington, DC: American Psychiatric Association; 1994.Google Scholar
31.Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:5662.Google Scholar
32.Montgomery, SA, Åsberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382389.Google Scholar
33.Guy, W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology. Rockvllle, MD: US Department of Health, Education, and Welfare; 1976.Google Scholar
34.Lipman, RS. Differentiating anxiety and depression in anxiety disorders: use of rating scales. Psychopharmacol Bull. 1982; 18:6977.Google Scholar
35.Raskin, A, Schulterbrandt, J, Reatlg, N, McKeon, JJ. Replication of factors of psychopathology in interview, ward behavior and self-report ratings of hospitalized depressives. J Nerv Ment Dis. 1969;148:8798.Google Scholar
36.Thase, ME, Kornstein, SG, Germain, J-M, Jiang, Q, Guico-Pabia, C, Ninan, PT. An Integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectr. 2009; 14:144154.Google Scholar
37.Thase, ME. Comparing the methods used to compare antidepressants. Psychopharmacol Bull. 2002;36(suppl 1):117.Google Scholar